Vasoactive intestinal polypeptide receptor antagonism enhances the vagally induced increase in cardiac interval of the rat atrium in vitro

被引:9
作者
Hogan, K [1 ]
Markos, F [1 ]
机构
[1] Univ Dublin Trinity Coll, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland
关键词
D O I
10.1113/expphysiol.2006.033605
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The effect of vasoactive intestinal polypeptide (VIP) receptor antagonism on preganglionic vagal electrical stimulation and on vagal postganglionic activation using nicotine and 1,1-dimethyl-4-phenylpiperazinium iodide on cardiac interval was evaluated in the isolated innervated rat right atrium. The vagus was stimulated at 4, 8, 16 and 32 Hz, pulse duration 1 ms, 20 V, for 30 s. All experiments were carried out in the presence of atenolol (4 mu M). Vagal stimulation caused a frequency-dependent increase in cardiac interval which was amplified significantly at each frequency, except at 32 Hz, following application of the VIP receptor antagonist VIP (6-28) at 2 nM in 15 rats. Application of the ganglionic antagonist hexmethonium (28 mu M, n = 7 rats) prior to 2 nM VIP (6-28) abolished this effect. Increasing the concentration of VIP(6-28) 10-fold to 20 nM did not result in a greater increase in cardiac interval than that obtained at 2 nM. Nicotine (0.1, 0.3, 0.5, 1.0 and 2.0 mM) increased cardiac interval by direct activation of postganglionic vagal fibres, but 2 nM VIP(6-28) did not affect the nicotine concentration response (n = 6 rats). 1,1-Dimethyl-4-phenylpiperazinium iodide (25, 50, 100 and 200 mu M; n = 6 rats) was also used to induce an increase in cardiac interval; again it was not significantly altered by 2 nM VIP(6-28). Therefore, VIP receptor antagonism enhances the magnitude of vagally induced cardiac slowing, probably via an action at the preganglionic-postganglionic synapse.
引用
收藏
页码:641 / 646
页数:6
相关论文
共 18 条
[1]   Vasoactive intestinal polypeptide modulation of nicotinic ACh receptor channels in rat intracardiac neurones [J].
Cuevas, J ;
Adams, DJ .
JOURNAL OF PHYSIOLOGY-LONDON, 1996, 493 (02) :503-515
[2]  
DALY MD, 1997, PERIPHERAL ARTERIAL, P597
[3]   A CHIMERIC VIP-PACAP ANALOG BUT NOT VIP PSEUDOPEPTIDES FUNCTION AS VIP RECEPTOR ANTAGONISTS [J].
FISHBEIN, VA ;
COY, DH ;
HOCART, SJ ;
JIANG, NY ;
MROZINSKI, JE ;
MANTEY, SA ;
JENSEN, RT .
PEPTIDES, 1994, 15 (01) :95-100
[4]   Vasoactive intestinal peptide: cardiovascular effects [J].
Henning, RJ ;
Sawmiller, DR .
CARDIOVASCULAR RESEARCH, 2001, 49 (01) :27-37
[5]   EFFECTS OF REPETITIVE VAGAL-STIMULATION ON HEART-RATE AND ON CARDIAC VASOACTIVE INTESTINAL POLYPEPTIDE EFFLUX [J].
HILL, MRS ;
WALLICK, DW ;
MARTIN, PJ ;
LEVY, MN .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 268 (05) :H1939-H1946
[6]   An investigation into the presence of a vagal tachycardia and the effect of vasoactive intestinal polypeptide on rat heart rate in vitro [J].
Hogan, K ;
Markos, F .
PHARMACOLOGY, 2006, 76 (02) :101-104
[7]   An investigation into the physiological relevance of the vagal tachycardia in the anaesthetized dog [J].
Markos, F. ;
Snow, H. M. .
ACTA PHYSIOLOGICA, 2006, 186 (03) :179-184
[8]   An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog [J].
Markos, F ;
Hennessy, BA ;
Fitzpatrick, M ;
O'Sullivan, J ;
Snow, HM .
PHARMACOLOGY, 2002, 66 (04) :206-210
[9]   The potentiation of sinus arrhythmia by vasoactive intestinal polypeptide (VIP) in the anaesthetized dog [J].
Markos, F ;
Snow, HM .
NEUROPEPTIDES, 2001, 35 (5-6) :238-243
[10]   VASOACTIVE-INTESTINAL-PEPTIDE RECEPTOR ANTAGONIST [4CL-D-PHE6, LEU17]VIP [J].
PANDOL, SJ ;
DHARMSATHAPHORN, K ;
SCHOEFFIELD, MS ;
VALE, W ;
RIVIER, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 250 (04) :G553-G557